SLC5A2 and hydrops fetalis: In the recent Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) trial, approximately two years of SGLT2 treatment significantly slowed renal function decline and reduced HF-related hospitalizations in HFpEF patients [9,10].